Results 131 to 140 of about 877,857 (301)

Kaplan-Meier Analysis of time to relapse.

open access: yes, 2017
Kaplan-Meier Analysis of time to relapse.
Marija Stojkovic (124558)   +3 more
core   +1 more source

“Low‐Positive” MOG‐IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the prevalence and clinical characteristics of patients with “low‐positive” (LP) MOG‐IgG (titres 1:160–1:320) among adults with a first demyelinating event (FDE) suggestive of multiple sclerosis (MS). Methods From the Barcelona CIS inception cohort, we included adult patients with serum collected ≤ 6 months from the FDE.
Javier Villacieros‐Álvarez   +29 more
wiley   +1 more source

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine   +40 more
wiley   +1 more source

The basics of Kaplan–Meier estimate

open access: yesJournal of the Practice of Cardiovascular Sciences, 2016
Aakshi Kalra
doaj   +1 more source

Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son   +3 more
wiley   +1 more source

Kaplan-Meier analysis of OS.

open access: yes, 2018
Kaplan-Meier curves for OS in in EGFR mutant lung adenocarcinoma receiving EGFR-TKI as first line therapy.
Yasushi Goto (491162)   +7 more
core   +1 more source

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui   +10 more
wiley   +1 more source

Kaplan-Meier curves for PFS.

open access: yes, 2019
Kaplan-Meier curves for PFS show a trend for reduced PFS for node-negative tumors with strong myofibroblastic reaction (Log rank: p = 0.075).
Jean-Christophe Noël (5654188)   +4 more
core   +1 more source

Clinical Impact of MGMT Promoter Methylation in IDH‐Mutant Gliomas: Influence of Threshold Selection and Clinical Confounding

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background The clinical relevance of MGMT promoter methylation in IDH‐mutant gliomas remains controversial in the era of molecular classification. We aimed to systematically evaluate its clinical relevance by integrating quantitative assessment, cutoff exploration, and adjustment for clinical confounding.
Haihui Jiang   +7 more
wiley   +1 more source

Evaluation of the Duration of Unemployment Spells Using Kaplan-Meier Estimator. A study on Botoşani County’s Labor Market [PDF]

open access: yesOvidius University Annals: Economic Sciences Series, 2018
The aim of this paper is analysing unemployment spells for Botoşani County’s labour market. The database includes individual information on a sample of 200 unemployment spells registeredat the Employment Agency of Botoşani County during January 2012 ...
Sandu Christiana Brigitte   +2 more
doaj  

Home - About - Disclaimer - Privacy